Sees FY24 Pharma sales lower in 2H vs.1H on Stelara. Says “very well positioned” to entertain many types of M&A deals. Says “agnostic” to sector or size when it comes to M&A. Says “very positive outlook” for Orthopedics business.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on JNJ:
- Johnson & Johnson (NYSE:JNJ) Drops Despite Q4 Beat
- Options Volatility and Implied Earnings Moves Today, January 23, 2024
- GLP-1 Anti-Obesity Drugs: Slim Waistlines, Fat Profits
- Options Volatility and Implied Earnings Moves This Week, January 22 – January 26, 2024
- JNJ Earnings this Week: How Will it Perform?
